Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Dees

Showing results (81-90 of 91) with videos related to

Pageof 10
Sort By:
Cancer Discovery|October 4, 2023
NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast CancerBrandie C Taylor, Xiaopeng Sun, Paula I Gonzalez-Ericsson, et al.
NEJM Evidence|July 23, 2024
Clinical and Genomic Risk for Late Breast Cancer Recurrence and SurvivalJoseph A Sparano, Michael Crager, Robert J Gray, et al.
Melanoma Research|March 4, 2021
Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922)Stergios J Moschos, Zeynep Eroglu, Nikhil I Khushalani, et al.
Journal of the National Cancer Institute|November 7, 2019
Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307Julie R Gralow, William E Barlow, Alexander H G Paterson, et al.
Cancer Research Communications|April 30, 2024
Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast CancerElizabeth C Wescott, Xiaopeng Sun, Paula Gonzalez-Ericsson, et al.
JAMA Oncology|October 1, 2019
Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical TrialJoseph A Sparano, Robert J Gray, Della F Makower, et al.
Journal of the National Cancer Institute|September 28, 2020
Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx TrialKathy S Albain, Robert J Gray, Della F Makower, et al.
The New England Journal of Medicine|June 4, 2019
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast CancerJoseph A Sparano, Robert J Gray, Peter M Ravdin, et al.
The New England Journal of Medicine|June 5, 2018
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast CancerJoseph A Sparano, Robert J Gray, Della F Makower, et al.
The New England Journal of Medicine|September 29, 2015
Prospective Validation of a 21-Gene Expression Assay in Breast CancerJoseph A Sparano, Robert J Gray, Della F Makower, et al.
Pageof 10

Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
Cancer Discovery|October 4, 2023
NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast CancerBrandie C Taylor, Xiaopeng Sun, Paula I Gonzalez-Ericsson, et al.
NEJM Evidence|July 23, 2024
Clinical and Genomic Risk for Late Breast Cancer Recurrence and SurvivalJoseph A Sparano, Michael Crager, Robert J Gray, et al.
Melanoma Research|March 4, 2021
Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922)Stergios J Moschos, Zeynep Eroglu, Nikhil I Khushalani, et al.
Journal of the National Cancer Institute|November 7, 2019
Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307Julie R Gralow, William E Barlow, Alexander H G Paterson, et al.
Cancer Research Communications|April 30, 2024
Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast CancerElizabeth C Wescott, Xiaopeng Sun, Paula Gonzalez-Ericsson, et al.
JAMA Oncology|October 1, 2019
Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical TrialJoseph A Sparano, Robert J Gray, Della F Makower, et al.
Journal of the National Cancer Institute|September 28, 2020
Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx TrialKathy S Albain, Robert J Gray, Della F Makower, et al.
The New England Journal of Medicine|June 4, 2019
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast CancerJoseph A Sparano, Robert J Gray, Peter M Ravdin, et al.
The New England Journal of Medicine|June 5, 2018
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast CancerJoseph A Sparano, Robert J Gray, Della F Makower, et al.
The New England Journal of Medicine|September 29, 2015
Prospective Validation of a 21-Gene Expression Assay in Breast CancerJoseph A Sparano, Robert J Gray, Della F Makower, et al.
Pageof 10